Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination

E. Kelemen, T. Masszi, P. Reményi, A. Barta, K. Pálóczi

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

A radiation-free, non-myeloablative, myelosuppressive protocol, containing dibromomannitol and cytosine arabinoside, that remarkably reduced the frequency of transplant-related complications, such as veno-occlusive liver disease (VOLD), severe mucositis, bacterial sepsis, hemorrhagic cystitis, interstitial pneumonitis, has been applied in 19 CML patients, allotransplanted from identical siblings. Five patients were in accelerated phase. Acute GVHD developed in two patients and chronic GVHD occurred in 66% of patients. Follow-up was 3 to 7 1/4 years. Although only eight patients were under 30 years of age, and only two patients had a history of less than 1 year, the leukemia-free survival was 82%. There were four hematological relapses. The reduction in post-BMT complications has greatly enhanced quality of life. The nurses reported significant reduction of work-load. Savings in eliminating the need for irradiation, parenteral nutrition, and several antibiotics are also remarkable. The remarkable reduction of certain transplant-related complications shows some advantage against busulphan-preconditioning.

Original languageEnglish
Pages (from-to)747-749
Number of pages3
JournalBone Marrow Transplantation
Volume21
Issue number8
Publication statusPublished - Apr 2 1998

Fingerprint

Drug Combinations
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transplants
Mitobronitol
Busulfan
Mucositis
Cystitis
Cytarabine
Interstitial Lung Diseases
Parenteral Nutrition
Workload
Liver Diseases
Siblings
Sepsis
Leukemia
Nurses
Quality of Life
Radiation
Anti-Bacterial Agents
Recurrence

Keywords

  • Allogeneic BMT
  • Chronic myeloid leukemia
  • Dibromomannitol-containing non-myeloablative preconditioning
  • Identical
  • Transplant-related complications

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{94e01482706848198f3b6bca56dbe69a,
title = "Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination",
abstract = "A radiation-free, non-myeloablative, myelosuppressive protocol, containing dibromomannitol and cytosine arabinoside, that remarkably reduced the frequency of transplant-related complications, such as veno-occlusive liver disease (VOLD), severe mucositis, bacterial sepsis, hemorrhagic cystitis, interstitial pneumonitis, has been applied in 19 CML patients, allotransplanted from identical siblings. Five patients were in accelerated phase. Acute GVHD developed in two patients and chronic GVHD occurred in 66{\%} of patients. Follow-up was 3 to 7 1/4 years. Although only eight patients were under 30 years of age, and only two patients had a history of less than 1 year, the leukemia-free survival was 82{\%}. There were four hematological relapses. The reduction in post-BMT complications has greatly enhanced quality of life. The nurses reported significant reduction of work-load. Savings in eliminating the need for irradiation, parenteral nutrition, and several antibiotics are also remarkable. The remarkable reduction of certain transplant-related complications shows some advantage against busulphan-preconditioning.",
keywords = "Allogeneic BMT, Chronic myeloid leukemia, Dibromomannitol-containing non-myeloablative preconditioning, Identical, Transplant-related complications",
author = "E. Kelemen and T. Masszi and P. Rem{\'e}nyi and A. Barta and K. P{\'a}l{\'o}czi",
year = "1998",
month = "4",
day = "2",
language = "English",
volume = "21",
pages = "747--749",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination

AU - Kelemen, E.

AU - Masszi, T.

AU - Reményi, P.

AU - Barta, A.

AU - Pálóczi, K.

PY - 1998/4/2

Y1 - 1998/4/2

N2 - A radiation-free, non-myeloablative, myelosuppressive protocol, containing dibromomannitol and cytosine arabinoside, that remarkably reduced the frequency of transplant-related complications, such as veno-occlusive liver disease (VOLD), severe mucositis, bacterial sepsis, hemorrhagic cystitis, interstitial pneumonitis, has been applied in 19 CML patients, allotransplanted from identical siblings. Five patients were in accelerated phase. Acute GVHD developed in two patients and chronic GVHD occurred in 66% of patients. Follow-up was 3 to 7 1/4 years. Although only eight patients were under 30 years of age, and only two patients had a history of less than 1 year, the leukemia-free survival was 82%. There were four hematological relapses. The reduction in post-BMT complications has greatly enhanced quality of life. The nurses reported significant reduction of work-load. Savings in eliminating the need for irradiation, parenteral nutrition, and several antibiotics are also remarkable. The remarkable reduction of certain transplant-related complications shows some advantage against busulphan-preconditioning.

AB - A radiation-free, non-myeloablative, myelosuppressive protocol, containing dibromomannitol and cytosine arabinoside, that remarkably reduced the frequency of transplant-related complications, such as veno-occlusive liver disease (VOLD), severe mucositis, bacterial sepsis, hemorrhagic cystitis, interstitial pneumonitis, has been applied in 19 CML patients, allotransplanted from identical siblings. Five patients were in accelerated phase. Acute GVHD developed in two patients and chronic GVHD occurred in 66% of patients. Follow-up was 3 to 7 1/4 years. Although only eight patients were under 30 years of age, and only two patients had a history of less than 1 year, the leukemia-free survival was 82%. There were four hematological relapses. The reduction in post-BMT complications has greatly enhanced quality of life. The nurses reported significant reduction of work-load. Savings in eliminating the need for irradiation, parenteral nutrition, and several antibiotics are also remarkable. The remarkable reduction of certain transplant-related complications shows some advantage against busulphan-preconditioning.

KW - Allogeneic BMT

KW - Chronic myeloid leukemia

KW - Dibromomannitol-containing non-myeloablative preconditioning

KW - Identical

KW - Transplant-related complications

UR - http://www.scopus.com/inward/record.url?scp=0031918108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031918108&partnerID=8YFLogxK

M3 - Article

C2 - 9603396

AN - SCOPUS:0031918108

VL - 21

SP - 747

EP - 749

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -